257
Participants
Start Date
July 31, 2010
Primary Completion Date
May 31, 2014
Study Completion Date
December 31, 2016
temozolomide 60 mg x 21 days
Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
temozolomide 75 mg x 21 days
Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
ABT-888 20 mg x 21 days
20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
ABT-888 40 mg x 21 days
40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
Temozolomide 150 mg x 5 days
150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)\*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
ABT-888 40 mg x 5 days
40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
Highland Hospital of Rochester, Rochester
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester
Regional Cancer Center at Singing River Hospital, Pascagoula
Louisville Oncology at Norton Cancer Institute - Louisville, Louisville
CCOP - Kansas City, Prairie Village
Renown Institute for Cancer at Renown Regional Medical Center, Reno
Cedars-Sinai Medical Center, Los Angeles
Leeward Radiation Oncology, ‘Ewa Beach
Cancer Research Center of Hawaii, Honolulu
Queen's Cancer Institute at Queen's Medical Center, Honolulu
Hawaii Medical Center - East, Honolulu
Legacy Good Samaritan Hospital & Comprehensive Cancer Center, Portland
Rebecca and John Moores UCSD Cancer Center, La Jolla
University of Chicago Cancer Research Center, Chicago
Central Baptist Hospital, Lexington
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick
Collaborators (1)
National Cancer Institute (NCI)
NIH
NRG Oncology
OTHER
Radiation Therapy Oncology Group
NETWORK